Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Whole-Brain Radiotherapy × anlotinib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 3 Thyroid Neoplasms 2 Sarcoma 2 Whole-Brain Radiotherapy 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Proteinuria 1 Progression Free Survival(PFS) 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Leiomyosarcoma 1 HER2-Negative Breast Cancer 1 Carcinoma, Renal Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07443397 2026-03-02

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting

Whole-Brain Radiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡